Iranian Scientists Use Nanotechnology to Treat Cancer
“This drug plays an important role as an anti-tumor drug in the treatment of certain types of cancer and is used in the treatment of metastatic breast cancer, specially for the patients who have heart problems,” said Ahmad Pourahadi, the managing director of the company.
“The drug’s name is Sina Doxosome and it is also effective in the treatment of advanced ovarian cancer and acts as an important treatment option in reducing the growth and spread of cancer cells,” he added.
Noting that the drug is also applied as an effective solution in the treatment of Kaposi's sarcoma in patients with AIDS, Pourahadi said, “This product contains a drug that can selectively destroy cancer cells. The doxorubicin hydrochloride contained in this drug is surrounded by small liposomal spherical shells.”
“The concentration process in this drug allows the drug to be more effectively directed through the bloodstream to cancerous tissues,” he underlined.
In a relevant development in September, immunology researchers of Tehran University of Medical Sciences had also succeeded in producing engineered cells to increase anti-tumor effects in cancer patients.
Tahereh Soltan Touyeh, a Ph.D. student in Immunology at Tehran University of Medical Sciences, in this research entitled ‘evaluation of the effect of simultaneous reduction of the expression of A2aR adenosine receptor and Tim3 molecule on the activity of T cells, the creation of chimeric antigen receptors in in vitro and in vivo’ managed to produce engineered cells to increase the anti-tumor effect in cancer patients.
“This plan tried to increase the efficiency of the anti-mesothelin CART cells produced in the previous stages by simultaneously reducing the expression of two inhibitory receptors and to produce more efficient anti-mesothelin CAR T cells,” Soltan Touyeh said.
“This plan helps to increase the anti-tumor effects in cancers with high expression of mesothelin by producing more efficient engineered cells,” she added.
4155/v
